Currently available vaccines against severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) are highly effective but not able to keep the coronavirus disease 2019 …

The new SARS-CoV-2 variant of concern “Omicron” was recently spotted in South Africa and
spread quickly around the world due to its enhanced transmissibility. The variant became …

SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to
respiratory distress and death. A major unresolved question is whether prior immunity to …

Objectives Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS‐
CoV‐2) has been instrumental in detecting previous exposures and analyzing vaccine …

Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order to estimate
the duration of immunity induced by SARS‐CoV‐2 it is important to understand for how long …

The common goal of all vaccines developed against COVID‐19, although they have been
designed with different methods, is to develop an effective immunity and antibody response …

Background Two doses of mRNA vaccination have shown> 94% efficacy at preventing
COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize …

Background Children are underrepresented in the COVID-19 pandemic and often
experience milder disease than adolescents and adults. Reduced severity is possibly due to …

Background Heterogeneity of the population in relation to infection, COVID-19 vaccination,
and host characteristics is likely reflected in the underlying SARS-CoV-2 antibody …

Abstract SARS-CoV-2 viruses, responsible for the COVID-19 pandemic, continues to evolve
into new mutations, which poses a significant threat to public health. Current testing methods …